Veozah vs. Estrogen: Which Hot Flash Treatment Is Right for You?

For over seven decades, systemic estrogen stood as the sole pharmacological standard of care for severe menopausal hot flashes and night sweats.

However, for millions of women with a history of hormone-receptor-positive breast cancer, unexplained uterine bleeding, prior deep vein thrombosis, or personal preferences against hormone therapy, effective clinical options were historically limited to off-label antidepressants (SSRIs/SNRIs) or gabapentinoids, often with modest efficacy and burdensome sedative side effects.

In May 2023, the U.S. Food and Drug Administration (FDA) approved Veozah (fezolinetant), introducing the first non-hormonal medication designed specifically to target the neurological epicenter of menopausal thermoregulatory dysfunction.

How does fezolinetant block hypothalamic KNDy neuron hyperactivation, how does it compare head-to-head with transdermal bioidentical estrogen, what are the liver safety monitoring requirements, and how should you choose the right clinical pathway with your physician?

1. The Neurobiology of a Hot Flash: The KNDy Neuron Mechanism#

To understand how Veozah and estrogen work, one must examine the infundibular nucleus of the hypothalamus, which acts as the body's internal thermostat:

[THE HYPOTHALMIC THERMOREGULATORY CASCADE]

PRE-MENOPAUSE (Normal Ovarian 17β-Estradiol):
  - Circulating estrogen binds estrogen receptors on hypothalamic KNDy neurons
    (Kisspeptin, Neurokinin B, and Dynorphin expressing neurons).
  - Estrogen exerts continuous INHIBITORY BRAKE on Neurokinin B (NKB) secretion.
  - Thermoregulatory set-point remains stable within a normal 0.4°C neutral zone.
                            │
                            ▼ (Menopausal Estrogen Depletion)
                            │
MENOPAUSE (Loss of Estrogenic Brake):
  - KNDy neurons HYPERTROPHY and secrete excessive NEUROKININ B.
  - Neurokinin B binds and overstimulates NEUROKININ 3 (NK3) RECEPTORS.
  - Signals the heat-dissipation center that the body is overheating.
  - Triggers acute peripheral vasodilation, intense facial flushing, and profuse diaphoresis.

• How Estrogen Works: Restores the natural systemic hormonal feedback loop, re-applying the biological brake on KNDy neuron firing.
• How Veozah (Fezolinetant) Works: Acts directly as a competitive antagonist at the NK3 receptor. It leaves estrogen levels unchanged but physically blocks Neurokinin B from binding the receptor, restoring normal hypothalamic temperature regulation.

2. Head-to-Head Comparison: Veozah vs. Estrogen Therapy#

3. The Clinical Decision Matrix: Who Should Choose What?#

                      [CLINICAL PATHWAY DECISION ALGORITHM]
                                        │
        ┌───────────────────────────────┴───────────────────────────────┐
        ▼                                                               ▼
[CHOOSE VEOZAH (NON-HORMONAL)]                          [CHOOSE TRANSDERMAL ESTROGEN + HRT]
  - History of breast cancer (ER/PR positive).            - No contraindications to systemic hormones.
  - History of unprovoked DVT, PE, or stroke.             - Within 10 years of menopause or age < 60.
  - Unexplained abnormal vaginal bleeding.                - Seeking multi-organ protection (BONE, HEART, BRAIN).
  - Severe personal aversion to hormone therapy.          - Concomitant vaginal dryness (GSM) or joint pain.
  - Primary goal: ISOLATED HOT FLASH RELIEF.              - Seeking metabolic defense against VISCERAL FAT.

Scenario A: The Ideal Candidate for Veozah#

A 52-year-old woman who completed treatment for ER-positive early-stage breast cancer three years ago is now on an aromatase inhibitor (e.g., anastrozole) and experiences 12 to 15 debilitating hot flashes daily. Because systemic estrogen is strictly contraindicated, Veozah provides targeted neurological relief without estrogen receptor stimulation.

Scenario B: The Ideal Candidate for Systemic HRT#

A 50-year-old woman within two years of her final menstrual period experiences hot flashes, severe sleep disruption, rising LDL-C, and early osteopenia on her DEXA scan. Starting transdermal 17β-estradiol with oral micronized progesterone eliminates her hot flashes while simultaneously preserving bone mineral density, reducing cardiovascular risk, and preventing visceral fat gain.

4. Safety Considerations & Hepatic Monitoring for Veozah#

In the phase 3 SKYLIGHT 1 and SKYLIGHT 2 clinical trials published in The Lancet, fezolinetant demonstrated a favorable overall safety profile, but highlighted an important hepatic consideration:

VEOZAH HEPATIC SAFETY PROTOCOL:
• Incidence: Approximately 2.3% of women in clinical trials experienced transient elevations
  in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal.
• Required Testing: Comprehensive Metabolic Panel (CMP) assessing ALT, AST, and total bilirubin:
  1. Prior to initiating Veozah therapy (Baseline).
  2. At 3 months of continuous therapy.
  3. At 6 months of continuous therapy.
  4. At 9 months of continuous therapy.
• Discontinuation Criteria: Discontinue immediately if ALT/AST exceeds 5x normal, or if transaminases
  exceed 3x normal accompanied by total bilirubin > 2x normal or clinical jaundice/fatigue.

5. Summary Clinical Recommendations#

For women suffering from severe vasomotor symptoms, the therapeutic landscape in 2026 is broader and more personalized than ever before:

1. Estrogen Remains the Gold Standard for Multi-Organ Health: If you are within 10 years of menopause, under age 60, and have no contraindications, transdermal bioidentical estradiol paired with micronized progesterone provides the most comprehensive relief across vasomotor, skeletal, metabolic, and cardiovascular domains.
2. Veozah Is a Breakthrough for Hormone-Ineligible Women: If you cannot take estrogen due to oncologic or vascular contraindications, Veozah offers targeted, non-sedating neurological relief from hot flashes, provided liver enzymes are monitored according to protocol.

To understand why starting hormone therapy within the first ten years of menopause matters, read The Menopause 'Timing Window': Why Starting HRT Before 60 Matters.

Scientific References & Primary Literature#

1. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10374):305-320. doi:10.1016/S0140-6736(22)02677-8.
2. Johnson KA, Martin N, Nappi RE, et al. Efficacy and Safety of Fezolinetant in Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Phase 3 Trial (SKYLIGHT 2). J Clin Endocrinol Metab. 2023;108(8):1981-1997. doi:10.1210/clinem/dgad058.
3. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Management of Menopause-Associated Symptoms and Long-Term Health Outcomes. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028.
4. Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211-227. doi:10.1016/j.yfrne.2013.07.003.
5. U.S. Food and Drug Administration (FDA). Veozah (fezolinetant) tablets, for oral use: Prescribing Information. Reference ID: 5173367. Approved May 2023.

Track Your Liver Panels & Hormone Biomarkers with Meridian#

Monitoring your laboratory blood biomarkers over time gives you objective validation that your diet, exercise, and lifestyle habits are keeping your metabolic health and glucose tolerance in optimal ranges.

Meridian is an offline personal health vault for iPhone designed to give you complete ownership of your medical diagnostic data.

• Instant Lab Report Extraction: Take a photo or upload a PDF of your Comprehensive Metabolic Panels (ALT, AST, Total Bilirubin, eGFR), Lipid Panels, and Hormone levels from Quest, Labcorp, or your prescriber. Meridian extracts all biomarkers on-device using Apple VisionKit.
• Safety Protocol Monitoring: Track your quarterly hepatic enzyme trends on Veozah or lipid and glucose trajectories on hormone therapy with complete privacy.
• 100% On-Device & Private: Protected by hardware AES-256 encryption and FaceID. Zero cloud servers. Zero data tracking.

Take control of your menopausal health and medical privacy today. Download Meridian on the App Store and keep your diagnostic records organized, private, and secure.